- Created on the 1 April, 2017.
A proliferation-inducing ligand (APRIL) can also be called tumor necrosis factor ligand superfamily member 13 (TNFSF13) and it is a protein belonging to the TNF superfamily which is able to be recognised by the cell surface receptor TACI. APRIL is designed CD256 when using the cluster of differentiation terminology. It is known to display low levels of expression in normal cells and high levels of expression in tumors from different origins. In particular it shares two TNF receptor family members, BCMA and TACI with another TNF homolog, BlyS/BAFF, both of these have been reported to play essential functions in cancer and autoimmune disease.
APRIL has a major role in T cell survival and T-independent type II antigen responses, however it is also able to induce the survival or proliferation of non-lymphoid cells. Biologically active APRIL and BlyS/BAFF heterotrimers have been identified to be expressed in patients with systemic immune-based rheumatic diseases. Also, local production of APRIL is discovered in arthritic joints of patients with inflammatory arthritis. There are evidence that a soluble form of the high affinity BCMA receptor has the ability to inhibit the proliferative activity of APRIL in vitro, this leads to reducing the tumor cell proliferation. Whereas, APRIL-transfected cells are found to display an increased rate of tumor growth directly, this observation indicates that APRIL could be implicated in the regulation of tumor cell growth.
Human APRIL ELISA kit is designed for detecting in vitro quantitative concentrations of a proliferation-inducing ligand (APRIL) in human serum, plasma, tissue homogenates, cell lysates, cell culture supernatant and other biological fluids. This assay has a minimum sensitivity limit of < 2.45 ng/ml.
The minimum detection sensitivity level of a proliferation-inducing ligand using this human APRIL ELISA kit was 2.45 ng/ml. The dynamic assay range for this kit is 5.0 – 2,000.0 ng/ml.
- The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. (2013) 24 (3): 203-15. Review. Vincent F.B., et al.
- Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. (2014) 18 (4): 473-89. Review. Stohl W.
- Immune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligand. Semin Hematol. (2013) 50 Suppl 1: S89-99. Review. Liu X.G. and Hou M.
- Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. (2006) 118 (3): 281-92. Review. Haiat S., et al.
- Full Name: A Proliferation-Inducing Ligand(APRIL) ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum, Cell Culture Supernatant, Cell Lysates, Other Biological Fluids, Tissue Homogenates
- Sensitivity: < 2.45 ng/ml
OTHER RELATED ELISA KITS
- B-Cell Activating Factor (BAFF) ELISA Kit
- TNF-Related Apoptosis-Inducing Ligand (TRAIL) ELISA Kit
- Annexin V (ANX-V) ELISA Kit